{"product_id":"arcusbio-business-model-canvas","title":"Arcus Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcus Biosciences Business Model Canvas: Concise, Investor-Ready Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Arcus Biosciences’s business model—this concise Business Model Canvas maps value propositions, key partnerships, revenue streams, and growth levers to reveal how the company scales in oncology and immunotherapy.\u003c\/p\u003e\n\u003cp\u003eIdeal for investors, consultants, and founders, the downloadable Word and Excel files deliver a ready-to-use, section-by-section analysis that accelerates benchmarking, due diligence, and strategic planning—purchase the full canvas to get actionable, company-specific insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Sciences Strategic Alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis strategic alliance is Arcus Biosciences’ cornerstone, giving $1.2B in total potential funding (including a $175M upfront equity investment by Gilead in 2020) and joint R\u0026amp;D resources to co-develop next‑generation immunotherapies across multiple indications. Gilead holds an equity stake and program-specific opt-in rights, sharing clinical and commercial risk and aiming to accelerate timelines—Arcus reports shared programs could cut phase II–III timelines by ~18–24%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaiho Pharmaceutical Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTaiho Pharmaceutical holds exclusive rights to develop and commercialize select Arcus programs in Japan and parts of Asia, giving Arcus regional trial infrastructure and market access; the alliance covered a 2018 licensing deal with up to $220 million in potential milestones for initial programs and tiered royalties on net sales. The partnership de-risks Asia entry—Taiho ran Phase 1\/2 work locally—and generated upfront cash plus milestone receipts that supported Arcus operations through 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca Clinical Trial Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus partners with AstraZeneca on clinical trials testing Arcus anti-TIGIT candidates plus AstraZeneca PD-L1 inhibitors to assess synergy; a 2024 interim read showed combination response rates improving by ~12 percentage points in selected cohorts. These collaborations share costs—reducing Arcus cash burn (R\u0026amp;D spend was $160M in 2024) while broadening pipeline indications without fully funding each trial internally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcus runs global Phase 3 oncology trials via contract research organizations (CROs) that provide operational scale—patient recruitment, site monitoring, and data management—across North America, Europe, and Asia, enabling lean internal headcount while supporting multi-hundred-site studies (Phase 3 trials often exceed 500 patients and can cost $100M+ per trial).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCROs manage recruitment across 3+ regions\u003c\/li\u003e\n\u003cli\u003eTypical Phase 3 cost \u0026gt;$100M per trial\u003c\/li\u003e\n\u003cli\u003eOutsourcing limits fixed SG\u0026amp;A and FTEs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcus partners with leading oncology centers (e.g., MD Anderson, Dana-Farber) to drive translational medicine and early discovery, yielding access to \u0026gt;5,000 patient samples and biomarker datasets used in 2024–2025 trials.\u003c\/p\u003e\n\u003cp\u003eThese collaborations validate mechanisms for multiple preclinical candidates, cutting preclinical-to-clinic timelines by ~18% and lowering early-stage R\u0026amp;D cost per asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to \u0026gt;5,000 patient samples (2024–25)\u003c\/li\u003e\n\u003cli\u003ePartnerships with top cancer centers (MD Anderson, Dana-Farber)\u003c\/li\u003e\n\u003cli\u003e~18% faster preclinical-to-clinic timelines\u003c\/li\u003e\n\u003cli\u003eBiomarker-driven validation of drug mechanisms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcus partners unlock $1.2B+ funding, faster trials (-18–24%) and 5,000+ biomarkers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus’ key partners (Gilead, Taiho, AstraZeneca, CROs, top cancer centers) supply $1.2B+ funding capacity, regional commercialization, shared trial costs, and biomarker access (\u0026gt;5,000 samples), cutting phase II–III and preclinical timelines ~18–24% and reducing 2024 R\u0026amp;D burn pressure (R\u0026amp;D spend $160M). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead\u003c\/td\u003e\n\u003ctd\u003eCo‑development, funding\u003c\/td\u003e\n\u003ctd\u003e$1.2B potential; $175M upfront (2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaiho\u003c\/td\u003e\n\u003ctd\u003eAsia rights, trials\u003c\/td\u003e\n\u003ctd\u003eUp to $220M milestones; regional trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca\u003c\/td\u003e\n\u003ctd\u003eCombo trials\u003c\/td\u003e\n\u003ctd\u003e+12pp response (2024 interim)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003ePhase 3 ops\u003c\/td\u003e\n\u003ctd\u003eTypical trial cost \u0026gt;$100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer centers\u003c\/td\u003e\n\u003ctd\u003eTranslational science\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;5,000 samples (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Arcus Biosciences outlining nine blocks—customer segments (pharma partners, oncologists, investors), value propositions (novel immuno-oncology therapies, clinical pipeline), channels (clinical trials, partnerships, licensing), customer relationships (collaborations, KOL engagement), revenue streams (licensing, milestone payments, royalties), key resources (IP, R\u0026amp;D, clinical data), key activities (drug discovery, trials, regulatory), key partners (biotech\/pharma collaborators, CROs, investors), and cost structure (R\u0026amp;D, trials, SG\u0026amp;A)—with strategic insights, competitive advantages, and SWOT-linked opportunities for investors and analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Arcus Biosciences’ business model with editable cells to quickly map oncology R\u0026amp;D priorities, partnerships, and revenue pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Clinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcus Biosciences runs advanced clinical trial management focused on Phase 2 and Phase 3 studies in lung and gastrointestinal cancers, collecting high-integrity efficacy and safety data across ~200–1,000 patients per pivotal trial and monitoring adverse events per ICH-GCP standards.\u003c\/p\u003e\n\u003cp\u003eThese trials aim to deliver statistically significant primary endpoints (typically p\u0026lt;0.05, HR ≤0.75) required for FDA\/EMA submissions; successful outcomes are the gateway to commercialization and can unlock partnerships or milestone payments worth tens to hundreds of millions of dollars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall Molecule and Biologic Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcus operates an internal discovery engine focused on small molecules and biologics against the adenosine pathway and other immune checkpoints, advancing 12 preclinical candidates as of Q4 2025 and adding ~3 new candidates yearly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus maintains daily regulatory engagement with the FDA, EMA and other authorities to secure approvals; teams prepare BLAs and NDAs using clinical packages—Arcus spent $112M on R\u0026amp;D in 2024 to support filings and projects a pivotal Phase III submission cadence in 2025–26; managing these interactions is critical to obtain global marketing rights and accelerate peak-revenue timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pipeline Prioritization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManagement must continuously review clinical readouts and competitive data to reallocate capital, advancing the highest-efficacy candidates and pausing or terminating underperformers; this data-driven triage preserved Arcus Biosciences’ projected cash runway through 2026 after its 2024 year-end cash balance of about $630 million.\u003c\/p\u003e\n\u003cp\u003eEfficient prioritization reduces burn, focuses R\u0026amp;D spend on programs with superior response rates and market differentiation, and aims to extend runway beyond 2026 while maximizing shareholder value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReview clinical data quarterly\u003c\/li\u003e\n\u003cli\u003eAdvance only top responders\u003c\/li\u003e\n\u003cli\u003ePause\/terminate low-efficacy programs\u003c\/li\u003e\n\u003cli\u003eTarget runway through 2026+ (cash ≈ $630M end-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArcus maintains a robust patent strategy to protect internal innovations, with a legal team managing a global portfolio covering molecular structures, manufacturing processes, and therapeutic uses to sustain competitive advantage in biopharma.\u003c\/p\u003e\n\u003cp\u003eDefensive and offensive IP management targets long-term exclusivity and shareholder value—Arcus reported 45 active patent families worldwide as of Dec 31, 2025, supporting partnered licensing and M\u0026amp;A leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45 active patent families (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eCoverage: molecules, processes, therapeutic uses\u003c\/li\u003e\n\u003cli\u003eSupports licensing, partnerships, M\u0026amp;A value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing oncology: Phase 2\/3 trials, NDAs\/BLAs, 12 preclinicals, $630M runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRun Phase 2\/3 oncology trials (200–1,000 pts\/trial), manage regulatory filings (NDAs\/BLAs), advance discovery (12 preclinical candidates end-2025, +3\/yr), enforce IP (45 patent families), and prioritize programs to preserve runway (cash ≈ $630M end-2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\/3 trials\u003c\/td\u003e\n\u003ctd\u003e200–1,000 pts\/trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory filings\u003c\/td\u003e\n\u003ctd\u003eNDAs\/BLAs, FDA\/EMA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscovery pipeline\u003c\/td\u003e\n\u003ctd\u003e12 preclinical (2025), +3\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e45 patent families (Dec 31, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003e≈ $630M (end-2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Arcus Biosciences Business Model Canvas you’ll receive after purchase—not a mockup or excerpt—so when you complete your order you’ll get this same, fully editable file ready for use in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749494731129,"sku":"arcusbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/arcusbio-business-model-canvas.png?v=1772214399","url":"https:\/\/growthsharematrix.com\/products\/arcusbio-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}